Pediatr. praxi. 2014;15(3):138-140

Child with immunodeficiency - possibilities of solution

doc.MUDr.Vojtěch Thon, Ph.D.
Ústav klinické imunologie a alergologie, LF MU a FN u sv. Anny v Brně

1st part: Diagnostic approach

Early diagnosis of immunodeficiency makes possible early definitive therapy and avoids the complications of pretreatment infections.

B-cell defects constitute the majority of primary immunodeficiencies. All are characterized by the reduction in or absence of immunoglobulins

and/or specific antimicrobial antibodies. Consequently, substitution of immunoglobulin G (IgG) is the pillar of treatment. T-cell

immunodeficiency defects become apparent as combined T- and B-cell deficiencies.

Keywords: imunodeficiency, IVIG, SCIG, TREC, KREC, transplantation, screening

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Thon V. Child with immunodeficiency - possibilities of solution. Pediatr. praxi. 2014;15(3):138-140.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007; 27(5): 497-502. Go to original source... Go to PubMed...
    2. de Vries E. European Society for Immunodeficiencies (ESID) members. Patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol. 2012; 167(1): 108-119. Go to original source... Go to PubMed...
    3. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2011; 2: 1-26. Go to PubMed...
    4. Thon V. Intestinální mikroflóra v raném dětství - úloha při rozvoji infekčních a alergických chorob. Pediatr. praxi 2011; 12(4): 252-256.
    5. Tlaskalova-Hogenova H, Tuckova L, Mestecky J, et al. Interaction of mucosal microbiota with the innate immune system. Scand J Immunol. 2005; 62(Suppl 1): 106-113. Go to original source... Go to PubMed...
    6. Brandtzaeg P, Kiyono H, Pabst R, Russell MW. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol. 2008; 1(1): 31-37. Go to original source... Go to PubMed...
    7. Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011; 8(2): 110-120. Go to original source... Go to PubMed...
    8. Hoernes M, Seger R, Reichenbach J. Modern management of primary B-cell immunodeficiencies. Pediatr Allergy Immunol. 2011; 22(8): 758-769. Go to original source... Go to PubMed...
    9. Thon V, Vlkova M, Chovancova Z, et al. Flow Based Enumeration of Plasmablasts in Peripheral Blood After Vaccination as a Novel Diagnostic Marker for Assessing Antibody Responses in Patients with Hypogammaglobulinaemia. In: Clinical Flow Cytometry - Emerging Applications, M.Sc. Ingrid Schmid (Ed.), ISBN: 978-953-51-0575-6, InTech 2012: 125-142. Go to original source...
    10. Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9: 722-728. Go to original source... Go to PubMed...
    11. Gathmann B, Mahlaoui N, Gérard L, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014 Feb 27. [Epub ahead of print]. Go to original source... Go to PubMed...
    12. Thon V, Wolf HM, Sasgary M, et al. Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients. Clin Exp Immunol. 1997; 110(2): 174-181. Go to original source... Go to PubMed...
    13. Cavaliere FM, Milito C, Martini H, et al. Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency. J Clin Immunol. 2013; 33(4): 838-846. Go to original source... Go to PubMed...
    14. Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol. 2007; 122(2): 156-162. Go to original source... Go to PubMed...
    15. Thon V. Importance of screening of IgG anti-IgA antibodies in hypogammaglobulinemic subjects to prevent anaphylactoid reactions. Klinická imunológia a alergológia 2010; 20(3): 26-27.
    16. Thon V, Vlková M, Litzman J, Lokaj J. Jednoduchá metoda k průkazu CD154 (CD40L) na lymfocytech v periferní krvi. Epidemiol Mikrobiol Imunol. 2010; 59(3): 147-154.

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.